现代生物医学进展2024,Vol.24Issue(22) :4389-4392.DOI:10.13241/j.cnki.pmb.2024.22.057

维奈克拉联合阿扎胞苷对老年急性髓系白血病患者T淋巴细胞亚群的影响及其疗效的影响因素分析

Analysis of the Effect of Venetoclax Combined with Azacytidine on T Lymphocyte Subsets in Elderly Patients with Acute Myeloid Leukemia and the Influencing Factors of its Efficacy

邹娟 冯梦菁 王文静 晁瑶 郑转珍
现代生物医学进展2024,Vol.24Issue(22) :4389-4392.DOI:10.13241/j.cnki.pmb.2024.22.057

维奈克拉联合阿扎胞苷对老年急性髓系白血病患者T淋巴细胞亚群的影响及其疗效的影响因素分析

Analysis of the Effect of Venetoclax Combined with Azacytidine on T Lymphocyte Subsets in Elderly Patients with Acute Myeloid Leukemia and the Influencing Factors of its Efficacy

邹娟 1冯梦菁 2王文静 3晁瑶 3郑转珍4
扫码查看

作者信息

  • 1. 山西医科大学第二临床医学院 山西太原 030001;邻水县人民医院肿瘤科 四川广安 638500
  • 2. 邻水县人民医院肿瘤科 四川广安 638500
  • 3. 山西医科大学第二临床医学院 山西太原 030001
  • 4. 山西医科大学第二医院血液内科 山西太原 030001
  • 折叠

摘要

目的:观察维奈克拉联合阿扎胞苷对老年急性髓系白血病(AML)患者T淋巴细胞亚群的影响,并分析疗效的影响因素.方法:238例老年AML患者根据治疗方案的不同分为对照组120例(接受阿扎胞苷治疗)和研究组118例(维奈克拉联合阿扎胞苷治疗).对比两组疗效、T淋巴细胞亚群变化情况、不良反应发生率.多因素Logistic回归分析影响疗效不佳的因素.结果:与对照组相比,研究组治疗后临床总有效率更高,CD3+、CD4+、CD4+/CD8+更高,CD8+更低(P<0.05).两组不良反应总发生率对比未见差异(P>0.05).血小板计数(PLT)偏低、乳酸脱氢酶(LDH)偏高、查尔森合并症指数(CCI)评分偏高是疗效不佳的危险因素(P<0.05).结论:维奈克拉联合阿扎胞苷能够有效提高老年AML患者的临床疗效,改善免疫功能.此外,老年AML患者的疗效还受到PLT、LDH、CCI评分的影响.

Abstract

Objective:To observe the effect of venetoclax combined with azacytidine on T lymphocyte subsets in elderly patients with acute myeloid leukemia(AML),and to analyze the influencing factors of efficacy.Methods:238 elderly AML patients were divided into control group(n=120,treated with azacitidine)and study group(n=1 18,treated with venetoclax combine with azacitidine)according to the different treatment options.The efficacy,changes of T lymphocyte subsets and incidence of adverse reactions were compared in two groups.The influencing factors that affect the poor efficacy were analyzed by multivariate logistic regression.Results:Compared with control group,the total clinical effective rate in study group after treatment was higher,CD3+,CD4+,CD4+/CD8+were higher,and CD8+was lower(P<0.05).There was no difference in the total incidence of adverse reactions between two groups(P>0.05).Low platelet count(PLT),high lactate dehydrogenase(LDH),and high Chalson comorbidities index(CCI)score were risk factors for poor efficacy(P<0.05).Conclusion:Vinecra combined with azacytidine can effectively improve the clinical efficacy and immune function of elderly AML patients.In addition,the efficacy of elderly AML patients is also affected by PLT,LDH,and CCI scores.

关键词

维奈克拉/阿扎胞苷/老年/急性髓系白血病/T淋巴细胞亚群/疗效/影响因素

Key words

Venetoclax/Azacytidine/Elderly/Acute myeloid leukemia/T lymphocyte subsets/Efficacy/Influence factors

引用本文复制引用

出版年

2024
现代生物医学进展
黑龙江省森工总医院 哈尔滨医科大学附属第四医院

现代生物医学进展

CSTPCD
影响因子:0.755
ISSN:1673-6273
段落导航相关论文